G. Piot

1.0k total citations
21 papers, 698 citations indexed

About

G. Piot is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, G. Piot has authored 21 papers receiving a total of 698 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 7 papers in Surgery. Recurrent topics in G. Piot's work include Cancer Treatment and Pharmacology (5 papers), Renal cell carcinoma treatment (3 papers) and Testicular diseases and treatments (3 papers). G. Piot is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Renal cell carcinoma treatment (3 papers) and Testicular diseases and treatments (3 papers). G. Piot collaborates with scholars based in France, Belgium and Lebanon. G. Piot's co-authors include Jean‐Luc Raoul, J H Jacob, M. Boisdron‐Celle, Yacine Merrouche, Érick Gamelin, Alain Morel, Étienne Dorval, R. Delva, Denis Pezet and Andrew Kramar and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

G. Piot

21 papers receiving 679 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Piot France 9 467 159 148 140 105 21 698
P J Dady New Zealand 14 359 0.8× 99 0.6× 192 1.3× 182 1.3× 67 0.6× 25 815
M Hunt United States 13 590 1.3× 157 1.0× 267 1.8× 80 0.6× 33 0.3× 21 1000
Jonathan C. Yau United States 17 454 1.0× 144 0.9× 197 1.3× 73 0.5× 29 0.3× 33 768
David Topolsky United States 15 348 0.7× 127 0.8× 123 0.8× 54 0.4× 59 0.6× 39 884
T. Girinski France 13 200 0.4× 75 0.5× 163 1.1× 105 0.8× 217 2.1× 26 759
L. Shulman United States 9 245 0.5× 229 1.4× 120 0.8× 87 0.6× 38 0.4× 14 591
Joanna Dewar Australia 12 514 1.1× 228 1.4× 393 2.7× 133 0.9× 68 0.6× 23 970
Garry Forgeson New Zealand 14 494 1.1× 63 0.4× 229 1.5× 175 1.3× 36 0.3× 22 918
A. Robinson United Kingdom 12 393 0.8× 332 2.1× 241 1.6× 126 0.9× 58 0.6× 35 764
Jeffrey Schneider United States 15 592 1.3× 86 0.5× 160 1.1× 120 0.9× 41 0.4× 40 882

Countries citing papers authored by G. Piot

Since Specialization
Citations

This map shows the geographic impact of G. Piot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Piot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Piot more than expected).

Fields of papers citing papers by G. Piot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Piot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Piot. The network helps show where G. Piot may publish in the future.

Co-authorship network of co-authors of G. Piot

This figure shows the co-authorship network connecting the top 25 collaborators of G. Piot. A scholar is included among the top collaborators of G. Piot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Piot. G. Piot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lesimple, Thierry, Laurent Riffaud, Didier Frappaz, et al.. (2009). Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study. Journal of Neuro-Oncology. 93(2). 253–260. 9 indexed citations
3.
Coudert, Bruno, Mario Campone, M. Spielmann, et al.. (2009). Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial.. Cancer Research. 69(24_Supplement). 603–603. 8 indexed citations
4.
Spielmann, M., Henri Roché, T. Delozier, et al.. (2009). Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial. Journal of Clinical Oncology. 27(36). 6129–6134. 220 indexed citations
5.
6.
Martin, Laurent, et al.. (2004). Amifostine (A) reduces acute mucosal toxicity of accelerated radiotherapy (ART) and Carboplatin (CBP) in locally advanced head and neck cancer (HNSC). Journal of Clinical Oncology. 22(14_suppl). 5566–5566. 1 indexed citations
7.
Delva, R., D. Serin, M. Namer, et al.. (1995). 378 Taxol® (paclitaxel) 225mg/m2 by 3-hour infusion without G-CSF as a second line therapy in patients (PTS) with metastatic breast cancer (MBC). European Journal of Cancer. 31. S82–S82. 7 indexed citations
8.
Rougier, P, Mario Ghosn, G. Piot, et al.. (1992). Phase II Trial of 7-Day Continuous 5-Fluorouracil Infusion in the Treatment of Advanced Colorectal Carcinoma. Oncology. 49(1). 35–39. 8 indexed citations
9.
Droz, Jean‐Pierre, J. L. Pico, Mario Ghosn, et al.. (1991). Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer. European Journal of Cancer and Clinical Oncology. 27(7). 831–835. 36 indexed citations
10.
Droz, Jean‐Pierre, Pierre Ruffiè, G. Piot, et al.. (1990). Sarcoidosis and Testicular Germ Cell Tumor. Scandinavian Journal of Urology and Nephrology. 24(3). 171–173. 9 indexed citations
11.
Théodore, Christine, Mohamed Azab, Jean‐Pierre Droz, et al.. (1989). Treatment of high-risk gestational trophoblastic disease with chemotherapy combinations containing cisplatin and etoposide. Cancer. 64(9). 1824–1828. 33 indexed citations
12.
13.
Piot, G., Jean‐Pierre Droz, C Théodore, et al.. (1988). Phase II Trial with High-Dose Elliptinium Acetate in Metastatic Renal Cell Carcinoma. Oncology. 45(5). 371–372. 1 indexed citations
14.
Droz, Jean Pierre, G. Piot, Christine Théodore, et al.. (1988). Prognostic factors in advanced nonseminomatous testicular cancer a multivariate logistic regression analysis. Cancer. 62(3). 564–568. 57 indexed citations
15.
Jp, Droz, C Théodore, Marwan Ghosn, et al.. (1988). Twelve-year experience with chemotherapy in adult metastatic renal cell carcinoma at the Institut Gustave-Roussy.. PubMed. 4(2). 97–9. 14 indexed citations
16.
Droz, Jean‐Pierre, Christine Théodore, Mario Ghosn, et al.. (1988). Twelve-Year Experience With Chemotherapy in Adult Metastatic Renal Cell Carcinoma at the Institut Gus-tave-Roussy. The Journal of Urology. 140(5 Part 1). 1073–1074. 7 indexed citations
17.
Jp, Droz, et al.. (1987). Phase II trial of the association of doxorubicin, 5 FU and cis platinum in hormonally unresponsive metastatic carcinoma of the prostate.. PubMed. 243B. 235–42. 2 indexed citations
18.
Rougier, Philippe, C Théodore, G. Piot, et al.. (1987). Phase II trial of combined 5-fluorouracil plus doxorubicin plus cisplatin (FAP regimen) in advanced gastric carcinoma.. PubMed. 71(12). 1301–2. 5 indexed citations
19.
Lasser, P, et al.. (1986). [Isolated hepatic metastases. Treatment by intra-arterial chemotherapy using a subcutaneous access chamber].. PubMed. 15(6). 237–40. 1 indexed citations
20.
Rougier, P, et al.. (1984). Chimiothérapie des métastases hépatiques isolées. Utilisation d'un réservoir sous-cutané pour infusions intra-artérielles.. La Presse Médicale. 13(10). 620–620. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P J Dady Breakdown of academic impact, for papers by M Hunt Breakdown of academic impact, for papers by Jonathan C. Yau Breakdown of academic impact, for papers by David Topolsky Breakdown of academic impact, for papers by T. Girinski Breakdown of academic impact, for papers by L. Shulman Breakdown of academic impact, for papers by Joanna Dewar Breakdown of academic impact, for papers by Garry Forgeson Breakdown of academic impact, for papers by A. Robinson Breakdown of academic impact, for papers by Jeffrey Schneider
Rankless by CCL
2026